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Abstract
Background: Hantaan virus (HTNV) is the causative agent of the most severe form of a rodent-borne disease
known as hemorrhagic fever with renal syndrome (HFRS). A safe and effective HTNV vaccine is needed. Vaccination
with DNA constructs expressing fused antigen with bioactive factors, has shown promising improvement of
immunogenicity for viral agents in animal models, but the effect of fusion strategy on HTNV DNA vaccine has not
been investigated.
Results: DNA plasmids encoding the HTNV nucleocapsid protein (N) and glycoprotein (Gn and Gc) in fusion to the
extracellular domain of cytotoxic T-lymphocyte-associated-antigen 4 (eCTLA-4) targeting to antigen presenting cells
(APCs) were constructed. Intramuscular immunization of mice with plasmids expressing eCTLA-4-HTNV-N/GP fusion
proteins leads to a significant enhancement of the specific antibody response as well as cytotoxic T-lymphocyte
(CTL) response in C57BL/6 mice. Moreover, this effect could be further augmented when co-administered with CpG
motifs.
Conclusions: Modification of viral antigen in fusion to bioactive factor will be promising to confer efficient antigen
presentation and improve the potency of DNA vaccine in mice.
Background
Hantaan virus (HTNV) (Bunyaviridae family, Hantavirus
genus) is the causative agent of the most severe form of
a rodent-borne disease known as hemorrhagic fever
with renal syndrome (HFRS). Other hantaviruses that
are known to cause HFRS include Seoul virus (SEOV),
Dobrava virus (DOBV) and Puumala virus (PUUV),
which cause disease in Asia, Europe, Scandinavia, and
western Russia respectively [1]. In addition, a few hanta-
viruses have been identified to associate with outbreaks
of a highly lethal disease, hantavirus pulmonary syn-
drome (HPS), in the Americas [2]. Since hantaviruses
can cause epidemics with high morbidity, and currently
there is no proven therapy for hantaviral disease, a safe
and effective vaccine(s) against hantaviruses infection is
necessary. HTNV causes the most severe form of HFRS
and around 150,000 cases of HFRS are reported world-
wide annually, with the majority of HFRS occurring in
Asia [3].
Hantaviruses are enveloped, negative strands RNA
viruses consisting of three single RNA segments desig-
nated S (small), M (medium), and L (large), which
encode the nucleocapsid (N) protein, envelope glycopro-
teins (Gn and Gc), and the RNA polymerase respectively
[4]. As a key surface antigen, glycoproteins (Gn and Gc)
bear the epitopes which could elicit neutralizing antibo-
dies against hantavirus infection [5]. N-specific antibo-
dies are neither neutralizing nor protective, but may
play a role through cellular immune response [5].
Immunization with DNA vaccines encoding antigen
has been used to induce both humoral and cellular
immune responses and holds potential for developing
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DNA vaccine to hantavirus was also promising and pre-
viously explored. DNA vaccination with a plasmid con-
taining the SEOV M segment elicited neutralizing
antibody responses in mice and hamsters as well as a
certain level of cross-protection against HTNV [6,7]. A
HTNV M gene-based DNA vaccine conferred good pro-
tection against infection in hamster model and elicited
high levels of neutralizing antibodies in Rhesus monkeys
[8]. However, there are still concerns about the potency
of DNA vaccines, like a low level of protein expression
after DNA immunization.
One of interesting approaches, to improve the potency
of DNA vaccine, is to fuse a bioactive domain, like cyto-
toxic-T-lymphocyte-associated protein 4 (CTLA-4), to
viral antigens [9]. CTLA-4 consists of extracellular
domain, transmembrane domain and cytoplasmic
domain. As an inhibitory costimulatory molecule,
CTLA-4 normally plays a key role to downmodulate T-
cell activation by interaction with its ligand, B7 on anti-
gen presenting cells (APCs) [10,11]. However, the affi-
nity of CTLA-4 to the shared ligands, B7 is 10-20 times
higher than that of its counterpart, CD28 which pro-
v i d e sac o s t i m u l a t o r ys i g n a lt oA P C s[ 1 0 ] .R e c e n t l y ,
Axel et al demonstrated that without the cytoplasmic
domain of CTLA-4, the extracellular domain of CTLA-4
(eCTLA-4) alone can enhance TCR activation instead of
inhibitory function in the full-length form [12]. Lu et al
has observed an enhancement of specific immune
response in mice and woodchuck models conferred by
eCTLA4 fused with woodchuck hepatitis virus nucleo-
protein [13]. In addition, adjuvant effects of CpG motifs
have been shown to enhance antigen-specific immune
responses to protein vaccine in mice and human [14,15].
While the effects of CpG motifs co-delivery on immune
responses to DNA vaccination in mice are diverse
[16-18].
In this study, we first report to generate recombinant
HTNV DNA vaccine plasmids encoding HTNV N or
GP fused to eCTLA4, and evaluated their immunogeni-
city in C57BL/6 mice as well as the strategy of co-deliv-
ery with CpG motifs. Our results indicated that
eCTLA4 fusion strategy could enhance specific antibody
response and cellular immune response in mice gener-
ated by HTNV DNA vaccine. This adjuvant effect could
be further augmented when co-delivery with CpG
motifs.
Materials and Methods
Cells and viruses
The 293T, Vero E6 cells and Baby hamster kidney cell
( B H K )c e l l sw e r ep u r c h a s e df r o mA T C C( A T C Cn u m -
ber: CRL-1586) and cultured in Dulbecco modified
Eagle medium (DMEM) supplemented with 10% heat-
inactivated fetal calf serum, 100 U of penicillin, and 100
μg of streptomycin per ml at 37 with 5% CO2.H T N V
strain 84Fli, isolated from liver of a fatal fetus in China
[19], were grown in Vero E6 cells as previously
described [20,21].
Construction of plasmids for DNA vaccination
Plasmids expressing HTNV strain 84Fli N protein
(pcDNA3/S) and glycoproteins (Gn and Gc, pcDNA3/
M) were constructed previously [22] with pcDNA3
vector (Invitrogen, Karlsruhe, Germany). A plasmid,
pCTLA-4-C expressing eCTLA-4-antigen fusion pro-
tein, was a kind gift from Prof. Mengji Lu [13].
pCTLA-4-C was constructed on pcDNA3 vector back-
ground with antigen fragment inserted downstream of
eCTLA-4 between EcoRV and Xhol (BioLabs, USA)
restriction sites. The S and M fragments respectively
encoding N protein and glycoproteins (Gn and Gc)
were amplified by RT-PCR with the following primers
containing restriction enzyme sites (EcoRV and Xhol):
Sf o r w a r d :5 ’-GGA TAT CAT GGC AAC TAT GGA
GGA A-3’; S reverse: 5’-GCA CTC GAG TTA TAG
TTT TAA AGG CTC TTG GTT GG-3’,Mf o r w a r d :
5’-GGA TAT CAT GGG GGT ATG GAA GTG GCT
AGT A-3’; M reverse: 5’-GCA CTC GAG CTA TGA
CTT TTT ATG CTT TCT TAC AGG-3’.T h ea m p l i -
fied fragments of S and M were digested with EcoRV
and Xhol and then respectively inserted into the corre-
sponding site of pCTLA-4-C predigested with EcoRV
and Xhol to generate pcDNA3/eCTLA4-S and
pcDNA3/eCTLA4-M. Insertion of correct nucleotide
sequence was verified by sequencing. DNA plasmids
were prepared with the Giga plasmid purification kit
(QIAGEN, Germany), and then dissolved in phos-
phate-buffered saline (PBS) in a final concentration of
1m g / m l .
The S and eCTLA4-S fragments were also further
cloned into pET30a vector (Merck, Darmstadt, Ger-
many) respectively to generate pET30a/S and pET30a/
eCTLA-S for the identification of expression of HTNV
N and eCTLA4-N fusion protein in prokaryotic system
induced by isopropyl-beta-D-thiogalactoside (IPTG).
Expression and Identification of eCTLA4-HTNV N and
eCTLA4-GP fusion proteins
Prokaryotic expression of HTNV N and eCTLA4-NP
fusion protein was analyzed by sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) as
described previously [23]. 293T and BHK cell lines were
used for transfection experiment. Transient transfection
was performed by using Lipofectamine 2000 (Invitrogen,
USA) according to the manufacture’s instructions. Tran-
sient expression of fusion protein, eCTLA4-N and
eCTLA4-GP (Gn and Gc) was verified by western-blot
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described previously [23].
Immunization of mice with HTNV recombinant DNA
plasmid
Female 6-8 weeks old C57BL/6C mice (H-2K
b)w e r e
housed in the facility of Chinese Academy of Medical
Sciences Breeding Laboratories under specific-pathogen-
free conditions. Mice were pretreated by intramuscular
injection of 100 μl 0.25% bupivacaine [24] in quadriceps
with 50 μl in each side. 24 hours later, groups of mice
were injected intramuscularly (i.m.) three times at one
week interval with 100 μg of DNA plasmids in the pre-
sence or absence of 10 μg of CpG1826 motifs [25] (San-
gon Biotech, Shanghai, China). DNA plasmids
expressing HTNV N (or eCTLA4-N) and HTNV GP (or
eCTLA4-GP) were mixed equally with 50 μgo fe a c h .A
group of mice was injected i.m. with either 100 μgo f
pcDNA3 vector or 100 μl PBS alone as a negative con-
trol. Sera of 5 mice per group for serological assay were
collected before each immunization and one week after
third immunization, and for cellular immune response
assay were collected one week after second
immunization.
Serologic assays
HTNV N-specific IgG antibodies in mice sera were
determined, by enzyme-linked immunosorbent assay
(ELISA) in [26,27]. 96-well microtiter plates (Costar,
USA) coated with 100 μl of purified recombinant N pro-
tein of HTNV strain A9 at a concentration of 1 μg/ml
as described previously [23]. Hantaan virus glycoproteins
specific IgG antibodies were evaluated by IFA using
insect Sf9 cells infected with a recombinant baculovirus
expressing the glycoproteins (Gn and Gc) of HTNV
train A9 [23]. Titers of neutralizing antibody were also
determined by microneutralization (MN) assay as pre-
viously described [23].
Enzyme Linked Immunospot (ELISPOT) Assay
All antibodies and reagents used in cytokine ELISPOT
assays were purchased from BD/Pharmingen (San
Diego, CA, USA). BD™ ELISPOT plates (BD, USA)
were coated with 100 μlo fa n t i - m o u s eI F N - g Ab (5 μg/
ml in Coating Buffer) at 4°C overnight. The plates were
then blocked with Blocking Solution (RPMI1640) for 2
h at room temperature. 100 μl freshly isolated spleno-
cytes (5 × 10
5 cells) were added into each wells and sti-
mulated with a synthesized peptide (HTNV N protein
221-228: SVIGFLAL) at 10 μg/ml, or positive stimula-
tors TPA (20 ng/ml) and Ionomycin (1 μg/ml). The
plates were incubated for 24 h at 37°C with 5% CO2.
Development and counting of cytokine ELISPOTs were
performed following the manufacturer’sp r o c e d u r e s .
Spots were counted using an ELISPOT reader system
(ImmunoSpot
® Analyzer, USA).
Intracellular Cytokine Staining (ICS) Flow Cytometer
For the analysis of intracellular IFN-g cytokine, freshly
isolated splenocytes (5 × 10
6 cells) were incubated for 5
h at 37°C in RPMI containing 10% FBS and 10 μg/ml
peptides (HTNV N protein 221-228: SVIGFLAL), or a
positive stimulator brefeldin A (Sigma, USA) at 10 μg/
ml. After being stained with FITC-conjugated anti-CD8
antibody and PE-cy5 conjugated anti-CD3 antibody
(eBioscience, USA), cells were fixed with 4% paraformal-
dehyde in PBS for 15 min, and then were permeabilized
with 0.5% saponin (Sigma, USA) in PBS for 10 min.
Finally, cells were stained with PE-conjugated anti-
mouse IFN-g McAb. All the procedures of antibody
staining were performed at room temperature for 15
min. Cell samples were then analyzed with an Epics-
MCL Cytometer (Beckman Coulter, USA), and the data
were collected with EXPO32 ADC XL 4 Color Software.
Statistical analysis
Statistical significance of the data was determined by
using Student’s t test or ANOVA of the SPSS 10.0 soft-
ware. The antibody titers were log10 transformed to get
a normal distribution before statistical analysis. A P
value of < 0.05 was considered significant.
Ethical approval
According to the medical research regulation of Minis-
try of Health, China, this study was approved by the
ethics committee of China CDC, which uses interna-
tional guidelines to ensure confidentiality, anonymity,
and informed consent. Informed consent was obtained
from all study participants.
Results
Expression and identification of eCTLA4-N/GP fusion
proteins
The expressing of eCTLA4-N fusion protein was firstly
determined in prokaryotic system. Supernatant and cell
lysates of E.coli DH5a transformed with pET30a/
eCTLA-S or pET30a/S plasmid were analyzed by SDS-
PAGE (Figure 1A). Neither eCTLA4-N fusion protein
nor HTNV N was expressed into supernatant (Figure
1A, lane 1 and lane 3). Instead, eCTLA4-N fusion pro-
tein was shown in cell lysate (Figure 1A, lane 2) with
about 66KD of molecular weight (MW). HTNV N was
consistently seen in 50KD of MW (Figure 1A, lane 4)
which matches previous result [23]. The expression of
eCTLA4-N fusion protein was further examined by wes-
tern-blot from 293T cells transiently transfected with
pcDNA3/eCTLA4-S. As shown in Figure 1B, eCTLA4-N
fusion protein was detected by either N-specific
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N) or anti-mouse eCTLA-4 (eBioscience, USA)
(eCTLA4-N/anti-eCTLA4). As a control, the HTNV N
protein without fusion with eCTLA-4 was also detected
by monoclonal antibody L13F3 (NP/anti-N).
IFA was also used to verify the expression of eCTLA4-
N and eCTLA4-GP fusion proteins as described in
Methods. BHK cells were transiently transfected with
pcDNA3/eCTLA4-M or pcDNA3/eCTLA4-S construct.
The expression of eCTLA4-GP or eCTLA4-N fusion
protein was detected with Gc- specific antibody (Y22) or
N-specific antibody (L13F3) [28,29] respectively as
demonstrated in (Figure 1C, a and 1c). Furthermore,
eCTLA4-GP and eCTLA4-N fusion proteins could also
be captured by monoclonal antibody of anti-mouse
eCTLA-4 (Figure 1C-b and 1d).
Antibody responses to HTNV N and GP induced in mice
following immunization with plasmids expressing
eCTLA4-N/GP fusion protein
To evaluate whether eCTLA4 fusion strategy could
enhance immunogenicity on HTNV DNA vaccine, C57
mice were immunized with DNA plasmids expressing
HTNV N and GP, or eCTLA4-N and GP fusion proteins
with or without 10 μg of CpG1826 motifs. The antibody
immune response to HTNV N or GP was determined by
N-specific ELISA or IFA assays. (Figure 2) The levels of
N protein-specific IgG were found to be substantially
induced one week after first immunization in mice that
received pcDNA3/eCTLA4-S+M DNA plasmids alone or
with CpG1826 (Figure 2A), and significantly higher than
that of mice receiving pcDNA3/S+M DNA plasmids
alone or with CpG1826. One week after second injection,
mice immunized with pcDNA3/eCTLA4-S+M plasmids
plus CpG1826 showed significantly higher N protein-spe-
cific IgG antibody titers compared to groups of mice that
received pcDNA3/eCTLA4-S+M or pcDNA3/S+M DNA
plasmids alone (p < 0.05), and about 3.5-fold higher than
that of mice receiving pcDNA3/S+M DNA plasmids plus
CpG1826 though not achieved statistic significance. After
two boosts, all mice that received HTNV DNA vaccine
plasmids had substantial increase of N protein-specific
IgG antibody titers. DNA plasmids expressing eCTLA4-
N and GP fusion proteins, combined with CpG1826, eli-
cited the highest N protein-specific IgG antibody titers
one week after third immunization compared to all the
other groups (p < 0.05). In addition, we also observed
that the magnitude of glycoprotein specific IgG antibody
was significantly improved by vaccination with DNA
plasmids expressing eCTLA4-N and GP fusion proteins,
especially when combined with CpG1826 (Figure 2B). No
eCTLA-4-specific antibodies were detected in sera of
mice receiving DNA plasmids expressing fusion proteins
(data not shown), which is consistent with the results of
Lu et al [13]. These results indicate that eCTLA4 fusion
strategy and CpG motif could improve the immunogeni-
city of HTNV DNA vaccine.
Neutralization activity
Neutralizing antibodies, which conferring protective
immunity induced by DNA vaccine plasmids against
hantavirus were evaluated by microneutralization assays.
Figure 1 Expression and identification of fusion proteins of eCTLA4-HTNV N or eCTLA4-HTNV glycoproteins. (A) SDS-PAGE analysis of
eCTLA4-HTNV N fusion protein in supernatant (Lane 1) and cell lysates (Lane 2) of E.coli; N protein without eCTLA (Lane 3 and 4); (B) Western-
blot analysis of eCTLA4-HTNV N fusion protein from 293T cells transfected with DNA constructs, detected by either N-specific monoclonal
antibody L13F3 (eCTLA4-N/anti-N) or anti-mouse eCTLA-4 antibody (eCTLA4-N/anti-eCTLA4). As a control, the HTNV N protein without fusion
with eCTLA-4 was also detected by monoclonal antibody L13F3 (NP/anti-N). (C) Immuno-fluorescence assay of transient expression of eCTLA4-
HTNV GP detected with HTNV Gc specific monoclonal antibody Y22 or anti-mouse eCTLA-4 antibody (C-a and b); or transient expression of
eCTLA4-HTNV N fusion proteins detected with L13F3 and anti-mouse eCTLA-4 antibody (C-c and d).
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groups exhibited no neutralizing activity. In contrast,
immune sera collected 21 days after the first immuniza-
tion with 100 μg of HTNV DNA vaccine plasmids in
the presence or absence of CpG motifs showed neutra-
lizing antibody titers of 8 to 32 (reciprocal of the highest
dilution exhibiting 50% neutralization) against HTNV
strain 84Fli. Immunization with pcDNA3 vector didn’t
elicit any neutralizing antibody. Groups of mice receiv-
ing pcDNA3/eCTLA4-S+M plus CpG motifs, pcDNA3/
eCTLA4-S+M alone, or pcDNA3/S+M plus CpG motifs,
all achieved MN titers of ≧ 16. Only three of mice
receiving pcDNA3/S+M alone could achieve MN titers
of 16. The mean MN titer in mice vaccinated by
pcDNA3/eCTLA4-S+M plus CpG motifs or pcDNA3/
eCTLA4-S+M alone was significantly higher than that
of mice immunized with pcDNA3/S+M alone (p < 0.05).
These results indicated thate C T L A 4f u s i o ns t r a t e g y
combine with CpG motif could induce better magnitude
of neutralizing antibodies in mice against HTNV
infection.
eCTLA4 fusion strategy enhances CD8 T-cell responses
CD8+ T-cells play a vital role in protection against han-
tavirus infection by cell-mediated mechanisms. In order
to evaluate the CD8+ T-cell response to vaccination, the
splenocytes from mice vaccinated with DNA vaccine
plasmids 1 week after each immunization were restimu-
lated with HTNV N protein-specific peptides and ana-
lyzed by ELISPOT (Figure 3A). The splenocytes from
mice 1 week after third immunization were restimulated
and analyzed by Intracellular Cytokine Staining assay
(Figure 3B). Number of CD8+IFN-g-secreting spleno-
cytes was significantly higher than other groups (p <
0.01) at 21 days after 1st immunization in mice receiv-
ing CpG+peCTLA4-M+S vaccine (Figure 3A).
Table 1 Neutralizing antibody responses against HTNV in
mice 21 days after 1
st vaccination
Titers for 50%
neutralization
Vaccination groups Mouse no. Day 0 Day 21
CpG+pcDNA3/eCTLA4-S+M 1 < 8 16
2< 8 3 2
3< 8 3 2
4< 8 1 6
5< 8 1 6
pcDNA3/eCTLA4-S+M 1 < 8 16
2< 8 1 6
3< 8 1 6
4< 8 1 6
5< 8 3 2
CpG+pcDNA3/S+M 1 < 8 16
2< 8 1 6
3< 8 1 6
4< 8 1 6
5< 8 1 6
pcDNA3/S+M 1 < 8 16
2< 8 1 6
3< 8 1 6
4< 8 8
5< 8 8
pcDNA3 1 < 8 < 8
2< 8 < 8
3< 8 < 8
4< 8 < 8
5< 8 < 8
Figure 2 Kinetics of anti-HTNV N and anti-HTNV GP IgG antibody responses. Mice were intramuscularly immunized with 100 μgo fD N A
constructs with or without CpG motifs on day 0, day 7 and day 4 and bled before each immunization. HTNV N and GP specific IgG antibody
responses were evaluated by ELISA (A) and IFA (B) respectively. Antibody endpoint was reciprocal of the highest dilution of serum that conferred
optical density above cutoff or positive fluorescence signal. *p < 0.05 between two groups denoted by the capped line.
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+M plasmids plus CpG1826 motif demonstrated higher
frequencies of CD8+IFN+ T-cells to HTNV N protein-
specific peptides compared with all the other groups in
flow cytometery analysis. (Figure 3B). These results indi-
cate that eCTLA4 fusion strategy could enhance the
Th1-type cellular immune response.
Discussion
DNA immunization with plasmids expressing hantavirus
N protein and glycoprotein by intramuscular vaccination
induced specific immune responses to the correspond-
ing viral antigens in mice. In this study, we demon-
strated that, a better magnitude of humoral and cellular
immune responses could be generated in mice by DNA
vaccine plasmids encoding HTNV N and GP fused to
eCTLA4, a bioactive factor targeting to antigen present-
ing cells (APCs).
DNA vaccine has been demonstrated as a promising
vaccination strategy for various viral infections [30]. Pre-
vious studies have shown good immunogenicity and
protection efficacy of hantavirus DNA vaccine
[6,8,31,32]. Hooper et al. demonstrated that DNA vacci-
nation with a plasmid containing a cDNA representing
the Seoul virus (SEOV) M segment elicited neutralizing
antibody responses in mice and hamsters [6]. Gene gun
vaccination with this DNA construct protected hamsters
against infection with SEOV and HTNV [6,7]. They also
reported a HTNV M gene-based DNA vaccine conferred
sterile protection against infection in hamster model and
elicited high levels of neutralizing antibodies in nonhu-
man primates [8]. Kamrud et al. also demonstrated a
good immunogenicity of SEOV S gene-based DNA vac-
cine in hamster model [7]. Virus-neutralizing antibodies
could be induced slightly in BALB/c mice following vac-
cination with DNA constructs encoding overlapped pep-
tide fragments of Sin Nombre hantavirus (SNV) Gn and
Gc protein [33]. However, these authors failed to repro-
duce the neutralizing antibody findings in a subsequent
study with deer mouse model [34]. DNA vaccination
with Puumala virus (PUUV) S segment also induced
specific antibody response in mice [35]. Consistently, in
our study, an N or GP-specif i ca n t i b o d yr e s p o n s ew a s
detected respectively in mice after immunized with
equal mixture of HTNV S gene and M gene-based DNA
plasmids. A substantial level of neutralizing antibody
was elicited by HTNV DNA vaccine. As cellular
immune response also plays an important role in limit-
ing virus infection and replication, we further evaluated
the HTNV N-specific cellular immune response in vitro,
and did see a high frequency of CD8+/IFN+ T-cells in
mice receiving HTNV DNA vaccine.
Figure 3 HTNV N-specific cellular immune response following DNA vaccination. (A) HTNV N-specific IFN-g-producing CD8+ T cells
demonstrated by ELISPOT Assay in groups of mice following DNA immunization. 4 mice of each group were euthanized on day 7, day 14 and
day 21 after the first immunization. Splenocytes at 10
6 cells/well were tested in the presence of 10 μg/200 μl CTL epitope peptides M6. Number
of spot forming cells (SFCs)/10
6 spleenocytes 2 was shown as mean plus standard deviation bar. SFCs in group of mice receiving pcDNA3/
eCTLA4-S+M plasmids plus CpG motif was significantly higher than other groups (*p < 0.01) on day 21 after 1st immunization. (B) Detection of
CD8+ CTL response specific for the epitope of hantavirus N protein by intracellular cytokine staining assay. One week after final boost, mice
were euthanized. Splenocytes were restimulated with 10 μg/ml peptides (M6) for 5 h, and then stained with FITC-conjugated anti-CD8 and PE-
conjugated anti-mouse IFN-g McAbs. Mean frequencies of IFN-g+ CD8+ cells in each group were shown in the right upper quadrants. Mean
frequency of IFN-g+ CD8+ cells in group of mice receiving pcDNA3/eCTLA4-S+M plasmids plus CpG motif was significantly higher than other
groups (p < 0.05).
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gen by fusion to a cellular protein, like eCTLA-4, could
improve the efficacy of DNA vaccine[13,36-39]. Here we
constructed DNA plasmids encoding HTNV N or GP
fused to eCTLA-4 protein (pcDNA3/eCTLA4-S or M).
Compared to DNA vaccine encoding HTNV N or GP
alone, pcDNA3/eCTLA4-S (M) greatly improved the
speed and magnitude of HTNV specific humoral
immune response in mice. Lu et al. reported similar
modulation effect of eCTLA4 on woodchuck hepatitis
virus nucleoprotein in mice and woodchuck models
[13]. Nicholas and his colleagues also observed the
enhancement of immune responses to pro cathepsin B
antigen in sheep model by fusion to eCTLA4 [40] In
addition, there is a higher frequency of CD8+/IFN+ T-
cells in mice immunized with pcDNA3/eCTLA4-S (M)
DNA plasmids than that of pcDNA3/S (M). As the high
affinity of eCTLA4 to its B7 ligand of APCs, our results
indicated that eCTLA4 targeting may facilitate the anti-
gen intake and processing by APCs, which will possibly
improve the efficacy of DNA vaccine.
Another interesting finding of our study is that the effi-
cacy of HTNV DNA vaccine was augmented by CpG
motifs. When co-administration with CpG motifs, HTNV
DNA vaccine induced better immune responses in mice
compared with immunization with HTVN DNA vaccine
alone. Vaccination with pcDNA3/eCTLA4-S (M) DNA
plasmids plus CpG motifs elicited the highest antibody
and cellular immune responses compared to all the other
groups. Mice receiving pcDNA3/S (M) plus CpG motifs,
though showed lower antibody titer one week after first
immunization than that of mice vaccinated with pcDNA3/
eCTLA4-S (M) DNA plasmids alone, exhibited compar-
able antibody response after the second injection. The
recognition of CpG motifs is through toll-like receptor 9
(TLR-9) [41] and then induces a broad range of immuno-
logical effects on APCs [42]. Adjuvant effect of CpG motifs
have been demonstrated in mice, humans as well as other
species [14,15]. Thus, after co-delivery of CpG motifs with
HTNV DNA vaccine, it’s conceivable that APCs may be
activated firstly by CpG motifs, then display enriched cost-
imulatory molecules (including B7) on the surface. This
early event may provide a more efficient intake of antigen
mediated by eCTLA4 later on through binding with B7
ligand. This may, if any, at least partially explain the
observed augmentation of humoral and cellular immune
responses induced by HTNV DNA vaccine in combination
with CpG motifs.
In summary, we have demonstrated that eCTLA4
fusion strategy could enhance antibody response and
cellular immune response in mice generated by hantaan
virus DNA vaccine. This adjuvant effect could be further
augmented when co-delivery with CpG motifs. More
work should be done to elucidate the mechanism of
eCTLA4 fusion strategy. Overall, our results suggest
that modification of viral antigen will be promising to
confer efficient antigen presentation and improve the
potency of DNA vaccine.
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